# Nuclide record upfront-psma (trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/trials/upfront-psma/>
  a schema:MedicalTrial ;
  nuclide:kind "trial" ;
  schema:identifier "upfront-psma", "NCT04343885" ;
  schema:name "UpFrontPSMA"@en ;
  schema:alternateName "ANZUP sequential LuPSMA and docetaxel trial"@en ;
  schema:description "In men newly diagnosed with prostate cancer that has already spread widely, giving two doses of the radioactive drug lutetium-PSMA before starting chemotherapy cleared PSA to undetectable levels in more men than chemotherapy alone, without adding side effects."@en ;
  schema:url <https://nuclide.cc/trials/upfront-psma/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/39293461/>, <https://clinicaltrials.gov/study/NCT04343885>, <https://anzup.org.au/clinical-trial/upfrontpsma-trial/> ;
  nuclide:status "active" ;
  nuclide:tag "radioligand therapy", "prostate cancer", "hormone-sensitive", "first line" ;
  nuclide:phase "2" ;
  nuclide:related <https://nuclide.cc/drugs/pluvicto/>, <https://nuclide.cc/drugs/docetaxel/>, <https://nuclide.cc/indications/prostate-mhspc/>, <https://nuclide.cc/trials/psmaddition/>, <https://nuclide.cc/isotopes/lu-177/> .